Recent Analysts’ Ratings Changes for Ardelyx (ARDX)

Ardelyx (NASDAQ: ARDX) has recently received a number of price target changes and ratings updates:

  • 2/2/2018 – Ardelyx was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company’s lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. “
  • 2/2/2018 – Ardelyx was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 2/2/2018 – Ardelyx was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 1/30/2018 – Ardelyx was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $8.50 price target on the stock. According to Zacks, “Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company’s lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. “
  • 1/26/2018 – Ardelyx was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 1/23/2018 – Ardelyx was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company’s lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. “
  • 1/19/2018 – Ardelyx was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 1/3/2018 – Ardelyx was given a new $12.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 12/27/2017 – Ardelyx was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of Ardelyx Inc (NASDAQ:ARDX) opened at $6.40 on Monday. Ardelyx Inc has a 52 week low of $4.05 and a 52 week high of $15.40. The stock has a market capitalization of $304.22, a price-to-earnings ratio of -2.87 and a beta of 0.44.

Ardelyx (NASDAQ:ARDX) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.10. During the same period last year, the company earned ($0.65) earnings per share. research analysts predict that Ardelyx Inc will post -2.01 EPS for the current year.

Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.

Receive News & Ratings for Ardelyx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply